During the past decade, Yanqun Xiang conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Yanqun Xiang" are "Chemotherapy Effect" (1 trials), "EBV-DNA≤4000 Copy/ml" (1 trials), "Metastatic Nasopharyngeal Carcinoma" (1 trials), "Nasopharyngeal Carcinoma" (1 trials) and "T2-3N0 or T1-2N1" (1 trials). Many other conditions were trialed in "Yanqun Xiang" in a lesser frequency.

Most popular intervention types in "Yanqun Xiang" are "Drug" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Intensity modulated radiotherapy" (1 trials), "PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab" (1 trials) and "Toripalimab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Yanqun Xiang" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Yanqun Xiang". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Yanqun Xiang, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Yanqun Xiang, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".